Q1 EPS Estimates for HRTX Decreased by Northland Securities

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Equities researchers at Northland Securities reduced their Q1 2026 EPS estimates for shares of Heron Therapeutics in a research note issued on Thursday, March 26th. Northland Securities analyst C. Byrnes now forecasts that the biotechnology company will earn ($0.02) per share for the quarter, down from their prior forecast of ($0.01). The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.13) per share.

Several other equities research analysts have also recently commented on HRTX. Weiss Ratings reissued a “sell (e+)” rating on shares of Heron Therapeutics in a report on Thursday, January 22nd. Zacks Research cut Heron Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Thursday, February 26th. Finally, HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of Heron Therapeutics in a research note on Friday, January 9th. Three equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Heron Therapeutics presently has an average rating of “Hold” and a consensus target price of $4.50.

Heron Therapeutics Stock Performance

Heron Therapeutics stock opened at $0.78 on Monday. The firm has a 50 day simple moving average of $1.13 and a 200-day simple moving average of $1.21. The company has a debt-to-equity ratio of 10.59, a current ratio of 2.48 and a quick ratio of 1.51. The stock has a market capitalization of $147.76 million, a PE ratio of -6.03 and a beta of 1.26. Heron Therapeutics has a 12-month low of $0.75 and a 12-month high of $2.61.

Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Thursday, February 26th. The biotechnology company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.03) by $0.01. The company had revenue of $40.59 million for the quarter, compared to analyst estimates of $39.53 million.

Institutional Trading of Heron Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in HRTX. B. Riley Wealth Advisors Inc. acquired a new position in Heron Therapeutics in the second quarter worth approximately $26,000. Advisory Services Network LLC lifted its position in shares of Heron Therapeutics by 2,383.4% during the 4th quarter. Advisory Services Network LLC now owns 18,874 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 18,114 shares during the last quarter. PKS Advisory Services LLC bought a new stake in shares of Heron Therapeutics during the 3rd quarter worth $25,000. Russell Investments Group Ltd. bought a new stake in shares of Heron Therapeutics during the 2nd quarter worth $43,000. Finally, Jones Financial Companies Lllp grew its holdings in shares of Heron Therapeutics by 5,541.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 24,088 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 23,661 shares during the last quarter. 80.01% of the stock is owned by institutional investors and hedge funds.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.